Valsamma Eapen1, A K Gururaj. 1. Department of Psychiatry, Faculty of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates. veapen@uaeu.ac.ae
Abstract
BACKGROUND: Risperidone is a novel antipsychotic drug that has been tried in the treatment of several child psychiatric disorders. In an open clinical study, we evaluated the safety and efficacy of risperidone in children with developmental disorder and behavioral problems including attention-deficit/hyperactivity disorder (ADHD). METHOD: Twelve patients aged 4 to 14 years who had a DSM-IV-diagnosed developmental disorder and ADHD in addition to other behavioral problems, in particular aggression, were treated with risperidone for a period of up to 2 years with daily doses ranging from 1 to 3 mg. Data were gathered from December 2002 to December 2004. RESULTS: A positive clinical response was noted in 9 of the 12 patients within 3 months of study recruitment according to the Clinical Global Impressions-Improvement scale. Risperidone was well tolerated by all 12 patients. The most commonly reported side effect was sedation, which necessitated dosage reduction in 2 patients, but not discontinuation. CONCLUSIONS: Our findings suggest that risperidone may be an effective and safe treatment for children and adolescents with developmental disorder and disruptive behaviors.
BACKGROUND:Risperidone is a novel antipsychotic drug that has been tried in the treatment of several childpsychiatric disorders. In an open clinical study, we evaluated the safety and efficacy of risperidone in children with developmental disorder and behavioral problems including attention-deficit/hyperactivity disorder (ADHD). METHOD: Twelve patients aged 4 to 14 years who had a DSM-IV-diagnosed developmental disorder and ADHD in addition to other behavioral problems, in particular aggression, were treated with risperidone for a period of up to 2 years with daily doses ranging from 1 to 3 mg. Data were gathered from December 2002 to December 2004. RESULTS: A positive clinical response was noted in 9 of the 12 patients within 3 months of study recruitment according to the Clinical Global Impressions-Improvement scale. Risperidone was well tolerated by all 12 patients. The most commonly reported side effect was sedation, which necessitated dosage reduction in 2 patients, but not discontinuation. CONCLUSIONS: Our findings suggest that risperidone may be an effective and safe treatment for children and adolescents with developmental disorder and disruptive behaviors.
Authors: Jan Croonenberghs; Joerg M Fegert; Robert L Findling; Goedele De Smedt; Stefan Van Dongen Journal: J Am Acad Child Adolesc Psychiatry Date: 2005-01 Impact factor: 8.829
Authors: J R Zarcone; J A Hellings; K Crandall; R M Reese; J Marquis; K Fleming; R Shores; D Williams; S R Schroeder Journal: Am J Ment Retard Date: 2001-11
Authors: Richard P Malone; Greg Maislin; Muniya S Choudhury; Cynthia Gifford; Mary Anne Delaney Journal: J Am Acad Child Adolesc Psychiatry Date: 2002-02 Impact factor: 8.829
Authors: Shweta Anand; Henry Tong; Frank M C Besag; Esther W Chan; Samuele Cortese; Ian C K Wong Journal: Paediatr Drugs Date: 2017-06 Impact factor: 3.022
Authors: Eleni Karatza; Samit Ganguly; Chi D Hornik; William J Muller; Amira Al-Uzri; Laura James; Stephen J Balevic; Daniel Gonzalez Journal: Front Pharmacol Date: 2022-03-17 Impact factor: 5.810